Previous 10 | Next 10 |
home / stock / incr.u:cc / incr.u:cc news
Record revenue of $3 4 1 million in the first quarter of 2022 Adjusted EBITDA 2 increased almost 1 1 0% year-over-year to $8 million Net income of $ 6 million for the Q1 of 2022 compare d to ...
NEW YORK and TORONTO and HERZLIYA, Israel, May 16, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that it plans to release financial results for the first quarter of 2022 after ...
NEW YORK, TORONTO, and HERZLIYA, Israel, May 09, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) today announced that that Alex Rabinovitch, Chief Executive Officer and Amos Cohen, Chief Financi...
NEW YORK and TORONTO and HERZLIYA, Israel, May 03, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) today announced that Alexander Rabinovitch, CEO of InterCure, will participate in Alliance Glo...
Another record year with continued industry leading growth and profitability supported by focused strategy and execution Revenue growth expected to continue in the first quarter and throughout 2022 Strong balance sheet with $89 million cash supporting future profitable g...
Delay in publication of the Audited Results due to immaterial technical audit matters The Company expects the Audited Results will not differ from announced preliminary results NEW YORK and TORONTO and HERZLIYA, Israel, April 05, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd ...
Fourth quarter 2021 Revenue and Adjusted EBITDA 2 of $33 million and $9 million, representing an increase of almost 200% and 140% YoY, respectively Record fiscal year 2021 revenue and Adjusted EBITDA 2 of $89 million and $23 million, representin...
Fourth quarter 2021 Revenue and Adjusted EBITDA 2 of $33 million and $9 million, representing an increase of almost 200% and 140% YoY, respectively Record fiscal year 2021 revenue and Adjusted EBITDA 2 of $89 million and $23 million, representin...
Will release financial results for the fourth quarter of 2021 before market open on Monday, April 4, 2022 Webcast scheduled for same day at 8:30am ET NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U...
NEW YORK, TORONTO, and HERZLIYA, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) today announced that it plans to release financial results for the fourth quarter of 2021 afte...
News, Short Squeeze, Breakout and More Instantly...
Intercure Ltd. Ordinary Shares Company Name:
INCR.U:CC Stock Symbol:
TSXC Market:
Intercure Ltd. Ordinary Shares Website:
NEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (" InterCure " or the " Compan y "), the leading medical cannabis company in Israel and outside of North America, today addressed the status of the security ...
Achieved record revenues of NIS 209 million ($ 7 5 million) 1 for the first half of 2023 Annualized revenue run rate of NIS 41 7 million ($ 149 million) Adjusted EBITDA 2 of NIS 30 mill...
NEW YORK and TORONTO and HERZLIYA, Israel, June 09, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(" InterCure " or the " Compan y "), reports today that, further to the Company’s press release issued on February 1, 2023, wh...